Marble Wealth LLC Makes New Investment in Astrazeneca Plc $AZN

Marble Wealth LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,341 shares of the company’s stock, valued at approximately $586,000.

A number of other hedge funds have also recently modified their holdings of AZN. Triumph Capital Management acquired a new stake in Astrazeneca during the third quarter worth about $25,000. Bangor Savings Bank boosted its holdings in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Eagle Bay Advisors LLC purchased a new stake in shares of Astrazeneca in the 4th quarter valued at approximately $30,000. YANKCOM Partnership purchased a new stake in shares of Astrazeneca in the 4th quarter valued at approximately $31,000. Finally, TFC Financial Management Inc. increased its holdings in shares of Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock worth $32,000 after buying an additional 335 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

NYSE AZN opened at $176.28 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The company has a market cap of $273.39 billion, a P/E ratio of 26.47, a P/E/G ratio of 1.41 and a beta of 0.25. The stock has a 50-day moving average of $190.88 and a two-hundred day moving average of $184.54. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. As a group, analysts anticipate that Astrazeneca Plc will post 10.26 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AZN shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. Weiss Ratings began coverage on Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Monday. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.